Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
Neil J. Shah, MBBS
Advertisement
Articles by Neil J. Shah, MBBS
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
Advertisement
Latest Updated Articles
Data Suggest Need for Novel Therapies in Later-Line Metastatic RCCPublished: July 13th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Sevabertinib in Non-Squamous NSCLC
2
Tarlatamab Earns Traditional FDA Approval in ES-SCLC
3
FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas
4
FDA Traditionally Approves Daratumumab Regimen in AL Amyloidosis
5
